
For its fifth annual Europe conference, FlyPharma chose Copenhagen as its host city to address the latest supply chain challenges …

Novartis has signed a collaboration and license agreement with Pliant Therapeutics to develop and commercialise preclinical asset PLN-1474 which is …

The Irish biopharma company expects to complete most of the job cuts by end of this year and will take …

Novartis has announced that the European Commission has approved a label update for the up-titration of Cosentyx (secukunumab) to 300mg …

A new report has warned that poorly implemented electronic medication systems in the NHS could potentially lead to fatal medication …

The US FDA has approved GlaxoSmithKline’s Zejula (niraparib) for the use in advanced ovarian, fallopian tube, or primary peritoneal cancer …

When it comes to life sciences and patient outcomes, the UK’s destiny is inextricably tied to its relationship with the …

The FDA has granted marketing authorisation to Vertex’s Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of cystic fibrosis (CF), it …

A small study has found that the commonly prescribed medication for kids and teenagers with autism is no more effective …

Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …

US firm Biogen is hoping for approval to bring about a treatment that could slow the onset of Alzheimer’s disease. …

Takeda has acquired licensing for a first-in-class investigational coeliac disease therapy CNP-101/TAK-101. The Japanese pharma giant now has the rights …

Porton Biopharma has signed a modification to its existing agreement with the US National Institute of Health’s National Institute of …

Novo Nordisk has celebrated the launch of a new Pharmatech A/S branch office based in Singapore at a grand opening …

Israeli drug company Teva has said that it would offer $250 million in cash and a supply of Suboxone, an …

Cancer Research UK has embarked on a new international alliance with a plan to develop ‘radical new strategies’ and technologies …

The US FDA has approved Trikafta (elexacaftor/ivacaftor/tezacaftor) – the first triple combination therapy available for patients with most common cystic …

Prime Minister Boris Johnson may have agreed a withdrawal agreement with the European Union at the 11th hour, but despite …

The FDA has moved to expand the existing label for Alexion’s Ultomiris (ravulizumab-cwvz) to include the treatment of atypical haemolytic …

The EMA’s human medicines committee (CHMP) has recommended seven medicines for approval at its October 2019 meet including MSD’s Ervebo, …